<qa>  To evaluate and estimate the overall survival rate of patients with borderline resectable pancreI. To evaluate and estimate 18 months overall survival OS rate of patients with borderline resectable pancreatic ductal adenocarcinoma PDAC receiving neoadjuvant therapy. 